X
Edition:
United States

  • Business
    • Business Home
    • Legal
    • Deals
    • Aerospace & Defense
    • Finance
    • Autos
    • Reuters Summits
  • Markets
    • Markets Home
    • U.S. Markets
    • European Markets
    • Asian Markets
    • Global Market Data
    • Indices
    • Stocks
    • Bonds
    • Currencies
    • Comm & Energy
    • Futures
    • Funds
    • Earnings
    • Dividends
  • World
    • World Home
    • U.S.
    • Special Reports
    • Reuters Investigates
    • Euro Zone
    • Middle East
    • China
    • Japan
    • Mexico
    • Brazil
    • Africa
    • Russia
    • India
  • Politics
    • Politics Home
    • Election 2016
    • Polling Explorer
    • Just In
    • What Voters Want
    • Supreme Court
  • Tech
    • Technology Home
    • Science
    • Top 100 Global Innovators
    • Environment
    • Innovation
  • Commentary
    • Commentary Home
    • Podcasts
  • Breakingviews
    • Breakingviews Home
    • Breakingviews Video
  • Money
    • Money Home
    • Retirement
    • Lipper Awards
    • Analyst Research
    • Stock Screener
    • Fund Screener
  • Rio 2016
  • Pictures
    • Pictures Home
    • The Wider Image
    • Photographers
    • Focus 360
  • Video
Paracetamol no better than placebo for low back pain, study finds
  • Africa
    América Latina
  • عربي
    Argentina
  • Brasil
    Canada
  • 中国
    Deutschland
  • España
    France
  • India
    Italia
  • 日本
    México
  • РОССИЯ
    United Kingdom
  • United States
Science News | Wed Jul 23, 2014 6:58pm EDT

Paracetamol no better than placebo for low back pain, study finds

By Kate Kelland | LONDON

LONDON Paracetamol, a painkiller universally recommended to treat people with acute low back pain, does not speed recovery or reduce pain from the condition, according to the results of a large trial published on Thursday.

A study published in The Lancet medical journal found that the popular pain medicine was no better than placebo, or dummy pills, for hastening recovery from acute bouts of low back pain or easing pain levels, function, sleep or quality of life.

Researchers said the findings challenge the universal endorsement of paracetamol as the first choice painkiller for lower back pain.

"We need to reconsider the universal recommendation to provide paracetamol as a first-line treatment," said Christopher Williams, who led the study at the University of Sydney in Australia.

Lower back pain is the leading cause of disability worldwide. In the United States alone, costs relating to the condition are estimated to be more than $100 billion a year.

Currently, every back pain treatment guideline in the world recommends paracetamol as the first-line analgesic and Williams said this was despite the fact that no previous studies have provided robust evidence that it works in this condition.

In his trial, 1,652 people from Sydney with acute low back pain were randomly assigned to receive up to four weeks of paracetamol, either in regular doses three times a day, or as needed, or to receive placebos. All those involved received advice and reassurance and were followed up for three months.

The results showed no difference in the number of days to recovery between the treatment groups - with the average time to recovery coming out at 17 days for each of the groups given paracetamol, and at 16 days for the placebo group.

Paracetamol had no effect on short-term pain levels, disability, function, sleep quality, or quality of life, the researchers said, and the number of patients reporting negative side effects was similar in all groups.

Christine Lin, an associate professor at the George Institute for Global Health and the University of Sydney who also worked on the study, said the reasons for paracetamol failing to work for lower back pain were not well understood.

"While we have shown that paracetamol does not speed recovery from acute back pain, there is evidence that paracetamol works to relieve pain for a range of other conditions, such as headaches, some acute musculoskeletal conditions, tooth ache and for pain straight after surgery," she said in a statement about the findings.

"What this study indicates is that the mechanisms of back pain are likely to be different from other pain conditions, and this is an area that we need to study more."

Experts who were not directly involved praised the study but cautioned that guidelines should nevertheless not be changed on the basis of a single piece of research.

"More robust and consistent evidence, including verification of the results in other populations, is needed," Bart Koes and Wendy Enthoven from the Erasmus Medical Center in the Netherlands wrote in a Lancet commentary.

They also called for more studies on whether other simple analgesics could add extra benefits on top of giving advice and reassurance to patients.

(Editing by Robin Pomeroy)

Trending Stories

    Editor's Pick

    LIVE: Election 2016

    Sponsored Topics

    Next In Science News

    Piltdown breakdown: new details about a famed scientific hoax

    WASHINGTON Researchers applying modern forensic techniques to a century-old puzzle have laid bare intriguing new details about one of the most notorious scientific hoaxes on record, the so-called Piltdown Man, and are confident in the culprit's identity.

    What3words keeps Olympics visitors on track in Rio

    An innovative addressing system that assigns every patch of earth in the world an easy to remember three-word address is being used to help visitors get around at the Olympics in Rio de Jeneiro. Some 500,000 foreigners are expected to pass through the city during the Games that run until August 21.

    Paralysis partly reversed using brain-machine interface training

    Paraplegic patients recovered partial control and feeling in their limbs after training to use a variety of brain-machine interface technologies, according to new research published on Thursday in the journal "Scientific Reports."

    MORE FROM REUTERS

    From Around the Web By Taboola

    Sponsored Content By Dianomi

    X
    Follow Reuters:
    • Follow Us On Twitter
    • Follow Us On Facebook
    • Follow Us On RSS
    • Follow Us On Instagram
    • Follow Us On YouTube
    • Follow Us On LinkedIn
    Subscribe: Feeds | Newsletters | Podcasts | Apps
    Reuters News Agency | Brand Attribution Guidelines | Delivery Options

    Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Learn more about Thomson Reuters products:

    Eikon
    Information, analytics and exclusive news on financial markets - delivered in an intuitive desktop and mobile interface
    Elektron
    Everything you need to empower your workflow and enhance your enterprise data management
    World-Check
    Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks
    Westlaw
    Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology
    ONESOURCE
    The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs
    CHECKPOINT
    The industry leader for online information for tax, accounting and finance professionals

    All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.

    • Site Feedback
    • Corrections
    • Advertise With Us
    • Advertising Guidelines
    • AdChoices
    • Terms of Use
    • Privacy Policy